NCT07574489Not yet recruitingPhase 2
Whole Versus Partial Gland Boost During Prostate SBRT
Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 25 Dec 2026
- Primary completion date
- 25 Dec 2032
- Lead sponsor
- University of Nebraska
- Diseases
- Prostate cancer
- NCT number
- NCT07574489
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 160
- From 25 Dec 2026 to the primary completion date, 25 Dec 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment for prostate cancer
- Prior solid cancer diagnosis in the last 5 years
- History of prior circumferential resection of the rectum (such as LAR or APR)
Other illness
- Any history of anal or rectal cancer
- Any history of invasive carcinoma of the bladder
- History of inflammatory bowel syndromes not adequately controlled on current medication regimen
Other
- Urinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Who the study is looking for
- Adults ≥19 years of age
- Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered
- Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan
- PI-RADS 4 or 5 lesion seen on pretreatment MRI
- IPSS/AUA (Appendix D, E) symptom score less than 16
Age in the registry: 19 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fred & Pamela Buffet Cancer Center Coordinator of this site? Confirm its status | Omaha | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.